Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Celyad S.A.. (9/21/17). "Press Release: Celyad to Present at the Cantor Fitzgerald Global Healthcare Conference". Mont-Saint-Guibert.

Region Region New York, NY
  Country United States (USA)
Organisations Organisation Celyad S.A. (Euronext Brussels + Paris: CYAD, Nasdaq: CYAD)
  Group Celyad (Group)
  Organisation 2 Cantor Fitzgerald & Co.
  Group Cantor Fitzgerald (Group)
Products Product Cantor Fitzgerald Healthcare Conference 2017 New York
  Product 2 CYAD-01 (CAR-T NKG2D) CAR-T cell therapy
Index term Index term Celyad–Cantor Fitzgerald: investor conference, 201709 supply service Celyad presents at Cantor Fitzegerald Global Healthcare Conference in NY
Persons Person Jeanmart, Patrick (Celyad/Cardio3 BioSciences –201312–201812 CFO LEFT 12/18)
  Person 2 Gilham, David (Celyad 201609– VP RnD before Univ Manchester MCRC + Bristol Univ)

Celyad (Euronext Brussels and Paris, and NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced that Patrick Jeanmart, Chief Financial Officer and David Gilham, VP Research and Development of Celyad will present a corporate update at the upcoming Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27th, 2017 at 2:15 p.m. ET in New York, NY.

A live audio webcast of the presentation will be available on the Investor Relations section of Celyad’s website at, where it will be archived for approximately 90 days.

About Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell based therapies. Celyad utilizes its expertise in cell engineering to target cancer. Celyad’s Natural Killer Receptor based T-Cell (NKR-T) platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a single dose escalation Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and Boston, Massachusetts. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the NASDAQ Global Market, all under the ticker symbol CYAD.

Record changed: 2017-10-04


Picture [LSUS] – The Business Web Portal 650x112px

More documents for Celyad (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2019 Boston September 600x60px

» top